Work

ALPHA2 Study: ALLO-501A Allogeneic CAR T in LBCL, Updated Results Continue to Show Encouraging Safety and Efficacy with Consolidation Dosing

Year: 2021

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2021-146045

Authors: Lazaros J. Lekakis, Frederick L. Locke, Michael Tees, Sattva S. Neelapu, Shahbaz A. Malik, Mehdi Hamadani, Matthew J. Frank, Leslie L. Popplewell, Jeremy S. Abramson, Sven de Vos, Javier Munoz, Chu Ri Shin, Arun Balakumaran, Lynn Loomis-Navale, Lovely Goyal, Xiangdong Zhou, David B. Miklos

Institutions: University of Miami Health System, Sylvester Comprehensive Cancer Center, Moffitt Cancer Center, Colorado Blood Cancer Institute, The University of Texas MD Anderson Cancer Center, St David's Medical Center, Medical College of Wisconsin, Stanford Medicine, Stanford University, City Of Hope National Medical Center, Massachusetts General Hospital, University of California, Los Angeles, Mayo Clinic Hospital, Allogene Therapeutics (United States)

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3212699181

Cites:

Cited by: 45

Related to: 10